More than 43 million Chinese doses of Sinopharm vaccines have been used globally by Reuters

BEIJING (Reuters) – More than 43 million doses of COVID-19 vaccines produced by the state-backed Chinese company Sinopharm have been used on Sunday, with more than 34 million doses being used in China and the rest abroad.

The company (CNBG) affiliated with Sinopharm produces two anti-Covid-19 vaccines, one of which is developed by a unit in Beijing and has obtained approval for public use in China and emergency use in a number of countries, including Iraq, Pakistan and Morocco.

The second vaccine, developed by a unit of the company (CNBG) in Wuhan, has also received approval for emergency use in China.

“So far, more than 43 million doses of (CNPG) vaccines have been used … of which more than 34 million doses have been used in China,” the Chinese Central Television said.

In addition to these two vaccines, China has developed two other companies, Sinovac Biotech and Cansino Biology, which have received approval for use abroad.

These vaccines can be stored in normal cold temperatures, making them a more attractive option for many developing countries that face difficulty using competing products from Moderna and Pfizer that require much higher temperatures (DU 🙂 for long-term storage.

The Chinese Foreign Ministry said last week that Beijing was providing vaccine assistance to 53 developing countries and had export agreements with 22 countries.

(Prepared by Mustafa Saleh for the Arabic Bulletin – Edited by Suha Gadu)